The use of AT1R antagonists and ACEi is the current mainstay of the treatment of hypertension and associated disorders, and there is evidence that the use of ACEi and ARBs, despite initial concerns, can re-establish RAAS homeostasis in severe COVID-19. The gene discussed is AGTR1; the disease is COVID-19.